Merck Serono: REFLEX Study Results Show Treat
News Release October 25, 2010 Merck Serono: REFLEX Study Results Show Treatment with Rebif®Delays Conversion to MS in Patients with First Clinical Signs of the Disease • Study met its primary endpoint• Risk of converting to multiple sclerosis (McDonald criteria) was reduced by half in patients treated with Rebif® 44 mcg three times a week